Company Overview of Open Monoclonal Technology, Inc.
Open Monoclonal Technology, Inc. operates as a biotechnology company. It offers OmniRat, an antibody platform that generates human monoclonal antibodies based on transgenic rats. Open Monoclonal Technology, Inc. has a strategic alliance with Crystal Bioscience, Inc. The company was founded in 2007 and is based in Palo Alto, California.
2747 Ross Road
Palo Alto, CA 94303
Founded in 2007
Key Executives for Open Monoclonal Technology, Inc.
Founder, Chief Executive Officer and Director
Compensation as of Fiscal Year 2014.
Open Monoclonal Technology, Inc. Key Developments
Open Monoclonal Technology, Inc. Grants OmniAb License to the University of Nottingham
Mar 18 15
Open Monoclonal Technology, Inc. (OMT) has granted The University of Nottingham a license to OMT's proprietary OmniRat, OmniMouse and OmniFlic platforms for generation of human antibody therapeutics. The university will use the technology for novel cancer antigens. The OmniRat, OmniMouse and OmniFlic platforms will allow to make fully human antibodies that can be fast tracked into the clinic for the benefit of cancer patients.
EMD Serono and Open Monoclonal Technology, Inc. Expand Collaboration to Include Unlimited Access to OmniRat Human Antibody Platform
Oct 28 13
EMD Serono and Open Monoclonal Technology, Inc. announced expansion of their collaboration agreement from June 2012. Under the terms of the new agreement, EMD Serono will make an upfront payment to secure unlimited access to the OmniRat platform as well as success-based development milestones and royalties. Further details of the contract are not being disclosed.
Symphogen A/S and Open Monoclonal Technology, Inc. Announce Collaboration
Oct 15 13
Symphogen A/S and Open Monoclonal Technology, Inc. announced an alliance that provides Symphogen with unlimited access to OMT's OmniRat(R) and OmniMouse(R) platforms. Symphogen will use its proprietary B cell-based antibody identification technology, Symplex(TM), and access the diverse immune repertoires generated in OMT's transgenic animals to develop novel human therapeutic candidates.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries